We are live on ! Find out more

884 hedge funds and large institutions have $72.3B invested in Biogen in 2014 Q4 according to their latest regulatory filings, with 130 funds opening new positions, 343 increasing their positions, 279 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 54

27% more funds holding in top 10

Funds holding in top 10: 4152 (+11)

23% more repeat investments, than reductions

Existing positions increased: 343 | Existing positions reduced: 279

8% more funds holding

Funds holding: 818884 (+66)

2% more capital invested

Capital invested by funds: $71B → $72.3B (+$1.3B)

28% less call options, than puts

Call options by funds: $975M | Put options by funds: $1.36B

Holders
884
Holders Change
+66
Holders Change %
+8.07%
% of All Funds
23.57%
Holding in Top 10
52
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+26.83%
% of All Funds
1.39%
New
130
Increased
343
Reduced
279
Closed
54
Calls
$975M
Puts
$1.36B
Net Calls
-$382M
Net Calls Change
+$97.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$612M +$197M +609,082 +51%
Capital World Investors
27
Capital World Investors
California
$581M +$301M +930,000 +119%
Norges Bank
28
Norges Bank
Norway
$559M
MCM
29
Marsico Capital Management
Colorado
$546M -$41.2M -127,210 -7%
AllianceBernstein
30
AllianceBernstein
Tennessee
$535M -$30.8M -95,328 -6%
Morgan Stanley
31
Morgan Stanley
New York
$532M +$100M +309,905 +25%
O
32
OppenheimerFunds
New York
$517M +$23.1M +71,310 +5%
O
33
OrbiMed
New York
$507M +$98.5M +304,600 +26%
Massachusetts Financial Services
34
Massachusetts Financial Services
Massachusetts
$491M -$69.2M -214,000 -13%
UBS AM
35
UBS AM
Illinois
$416M -$223M -689,255 -36%
AQR Capital Management
36
AQR Capital Management
Connecticut
$408M +$30.2M +93,290 +8%
MAA
37
Managed Account Advisors
New Jersey
$352M -$14.7M -45,427 -4%
Deutsche Bank
38
Deutsche Bank
Germany
$322M +$18.7M +57,649 +6%
Legal & General Group
39
Legal & General Group
United Kingdom
$319M -$9.79M -30,274 -3%
MC
40
Montag & Caldwell
Georgia
$313M -$142M -437,467 -32%
DCP
41
DSM Capital Partners
Florida
$305M +$41.7M +128,837 +17%
Prudential Financial
42
Prudential Financial
New Jersey
$282M -$8.76M -27,080 -3%
Allianz Asset Management
43
Allianz Asset Management
Germany
$282M -$61.4M -189,774 -19%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$265M -$25.8M -79,782 -10%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$265M -$5.3M -16,387 -2%
BA
46
BlackRock Advisors
Delaware
$265M -$241M -745,660 -49%
BlackRock
47
BlackRock
New York
$244M +$4.76M +14,708 +2%
CS
48
Credit Suisse
Switzerland
$242M +$20.9M +64,607 +10%
Grantham, Mayo, Van Otterloo & Co (GMO)
49
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$236M -$33.7M -104,185 -13%
AL
50
AJO LP
Pennsylvania
$230M -$16.1M -49,900 -7%

BIIB Hedge Fund Activity: Q4 2014 in Review

884 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2014, worth a combined $72.3B — up 1.8% from $71B a quarter earlier.

Buyers outnumbered sellers: 130 funds opened new BIIB positions and 54 closed out — a net gain of 76 holders — while 343 added to existing stakes and 279 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $326M. The largest seller was Capital Research Global Investors, cutting an estimated $1.67B.

  • 884 institutional investors held Biogen (BIIB) as of Q4 2014, up from 818 in Q3 2014.
  • Funds reported $72.3B of Biogen stock for Q4 2014, up 1.8% quarter-over-quarter.
  • 130 funds opened new Biogen positions in Q4 2014 and 54 closed out, a net change of +76 holders.
  • The largest Biogen buyer in Q4 2014 was Wellington Management Group, an estimated $326M added.
  • The largest Biogen seller in Q4 2014 was Capital Research Global Investors, an estimated $1.67B sold.

Based on aggregated 13F filings for Q4 2014.